Pharmaceutical giant Gilead Sciences on Wednesday retracted its effort to score extended monopoly rights and tax breaks on its antiviral drug remdesivir, which scientists are evaluating as a possible treatment in the novel coronavirus pandemic.

Read more…

Continue reading…

Tech Power Publisher